Pub Date : 2025-01-30DOI: 10.3324/haematol.2024.287052
Qian Yan, Jinlin Liu
Not available.
{"title":"Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies.","authors":"Qian Yan, Jinlin Liu","doi":"10.3324/haematol.2024.287052","DOIUrl":"https://doi.org/10.3324/haematol.2024.287052","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30DOI: 10.3324/haematol.2024.286924
Dong Li, Sarah K Tasian, Gerald Wertheim, Susan R Rheingold, Kathrin M Bernt, Haley Newman, Luanne Wainwright, Donna M Wilmoth, Brian Thiel, Lea F Surrey, Elizabeth Margolskee, Vinodh Pillai, Minjie Luo, Michele E Paessler, Stephen P Hunger, Marilyn M Li, Yiming Zhong
Not available.
{"title":"Integrated genomic analysis to reduce chromosomal analysis for the diagnosis of pediatric hematologic malignancies: addressing the shortage of cytogenetic technologists.","authors":"Dong Li, Sarah K Tasian, Gerald Wertheim, Susan R Rheingold, Kathrin M Bernt, Haley Newman, Luanne Wainwright, Donna M Wilmoth, Brian Thiel, Lea F Surrey, Elizabeth Margolskee, Vinodh Pillai, Minjie Luo, Michele E Paessler, Stephen P Hunger, Marilyn M Li, Yiming Zhong","doi":"10.3324/haematol.2024.286924","DOIUrl":"https://doi.org/10.3324/haematol.2024.286924","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30DOI: 10.3324/haematol.2024.286091
Muhit Özcan,Ryan D Cassaday,Ewa Zarzycka,Erik Vandendries,Fan Zhang,Ying Chen,Alejandra Nieto,Fatih Demirkan,Pau Montesinos,Fevzi Altuntas
Inotuzumab ozogamicin (InO) is approved for treatment of relapsed/refractory acute lymphoblastic leukemia (R/R ALL). Previous studies reported higher rates of post- hematopoietic stem cell transplant (HSCT) hepatic sinusoidal obstruction syndrome (SOS) in patients receiving InO versus chemotherapy prior to HSCT. It is unknown if a lower InO dose would reduce risk of post-HSCT SOS or if it would impact efficacy. This study evaluated efficacy and safety of the currently approved InO starting dose and a lower dose in adults with R/R ALL who were eligible for HSCT and were identified as being at higher risk of post- HSCT SOS. This open-label, phase 4 study (NCT03677596) had 2 phases: in the run-in phase patients received InO at 1.2 mg/m2/cycle (n=22); in the randomized phase patients received InO starting at dose levels of 1.8 mg/m2/cycle (n=38) or 1.2 mg/m2/cycle (n=42). Primary endpoints were rate of SOS and rate of hematologic remission. Overall, SOS was reported in 10 patients (9.8%); all were post-HSCT SOS. In patients who proceeded to HSCT, post-HSCT SOS rates were 20%, 28.6%, 25.8%, and 16.7% in 1.2 mg/m2/cycle (run-in), 1.2 mg/m2/cycle (randomized), 1.2 mg/m2/cycle (run-in and randomized), and 1.8 mg/m2/cycle (randomized), respectively. The CR/CRi rates were 50.0%, 83.3%, 71.9%, and 68.4% in the respective subgroups. The study found that a starting dose of 1.2mg/m2/cycle demonstrated consistent efficacy and safety to the recommended 1.8 mg/m2/cycle dose in adults with R/R ALL who were eligible for HSCT and had a higher risk of post-HSCT SOS.
{"title":"Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study.","authors":"Muhit Özcan,Ryan D Cassaday,Ewa Zarzycka,Erik Vandendries,Fan Zhang,Ying Chen,Alejandra Nieto,Fatih Demirkan,Pau Montesinos,Fevzi Altuntas","doi":"10.3324/haematol.2024.286091","DOIUrl":"https://doi.org/10.3324/haematol.2024.286091","url":null,"abstract":"Inotuzumab ozogamicin (InO) is approved for treatment of relapsed/refractory acute lymphoblastic leukemia (R/R ALL). Previous studies reported higher rates of post- hematopoietic stem cell transplant (HSCT) hepatic sinusoidal obstruction syndrome (SOS) in patients receiving InO versus chemotherapy prior to HSCT. It is unknown if a lower InO dose would reduce risk of post-HSCT SOS or if it would impact efficacy. This study evaluated efficacy and safety of the currently approved InO starting dose and a lower dose in adults with R/R ALL who were eligible for HSCT and were identified as being at higher risk of post- HSCT SOS. This open-label, phase 4 study (NCT03677596) had 2 phases: in the run-in phase patients received InO at 1.2 mg/m2/cycle (n=22); in the randomized phase patients received InO starting at dose levels of 1.8 mg/m2/cycle (n=38) or 1.2 mg/m2/cycle (n=42). Primary endpoints were rate of SOS and rate of hematologic remission. Overall, SOS was reported in 10 patients (9.8%); all were post-HSCT SOS. In patients who proceeded to HSCT, post-HSCT SOS rates were 20%, 28.6%, 25.8%, and 16.7% in 1.2 mg/m2/cycle (run-in), 1.2 mg/m2/cycle (randomized), 1.2 mg/m2/cycle (run-in and randomized), and 1.8 mg/m2/cycle (randomized), respectively. The CR/CRi rates were 50.0%, 83.3%, 71.9%, and 68.4% in the respective subgroups. The study found that a starting dose of 1.2mg/m2/cycle demonstrated consistent efficacy and safety to the recommended 1.8 mg/m2/cycle dose in adults with R/R ALL who were eligible for HSCT and had a higher risk of post-HSCT SOS.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"17 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143062072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-23DOI: 10.3324/haematol.2024.286886
Barbara Gianesin, Frédéric B Piel, Khaled M Musallam, Susanna Barella, Maddalena Casale, Elena Cassinerio, Rosario Di Maggio, Antonia Gigante, Maria Rita Gamberini, Giovanna Graziadei, Roberto Lisi, Filomena Longo, Aurelio Maggio, Raffaella Origa, Annamaria Pasanisi, Silverio Perrotta, Antonio Giulio Piga, Valeria Maria Pinto, Rosamaria Rosso, Giacomo Robello, Giovanna Russo, Marco Zecca, Lucia De Franceschi, Gian Luca Forni
Not available.
{"title":"Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study.","authors":"Barbara Gianesin, Frédéric B Piel, Khaled M Musallam, Susanna Barella, Maddalena Casale, Elena Cassinerio, Rosario Di Maggio, Antonia Gigante, Maria Rita Gamberini, Giovanna Graziadei, Roberto Lisi, Filomena Longo, Aurelio Maggio, Raffaella Origa, Annamaria Pasanisi, Silverio Perrotta, Antonio Giulio Piga, Valeria Maria Pinto, Rosamaria Rosso, Giacomo Robello, Giovanna Russo, Marco Zecca, Lucia De Franceschi, Gian Luca Forni","doi":"10.3324/haematol.2024.286886","DOIUrl":"https://doi.org/10.3324/haematol.2024.286886","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Heat exposure and pediatric immune thrombocytopenia in Japan from 2011 to 2022: a nationwide space-time-stratified case-crossover study.","authors":"Nobutoshi Nawa, Hisaaki Nishimura, Kiyohide Fushimi, Takeo Fujiwara","doi":"10.3324/haematol.2024.287176","DOIUrl":"https://doi.org/10.3324/haematol.2024.287176","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-23DOI: 10.3324/haematol.2024.286618
Genevieve Douglas, Kane M Nicholls, Erin Paul, Zoe Loh, Sze-Ting Lee, Kathryn L Hackman, Cherie Chiang, Niamh Waters, Geoffrey Chong, Ashvind Prabahran, Eliza A Hawkes
Not available.
{"title":"Opportunistic bone density assessment using pre-treatment [18F]FDG-PET/CT identifies fracture risk in lymphoma patients undergoing corticosteroid-containing chemotherapy.","authors":"Genevieve Douglas, Kane M Nicholls, Erin Paul, Zoe Loh, Sze-Ting Lee, Kathryn L Hackman, Cherie Chiang, Niamh Waters, Geoffrey Chong, Ashvind Prabahran, Eliza A Hawkes","doi":"10.3324/haematol.2024.286618","DOIUrl":"https://doi.org/10.3324/haematol.2024.286618","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：